Mylan (MYL)
from Dow Theory Forecasts
Mylan (MYL) submitted an Abbreviated New Drug Application (ANDA) to U.S. regulators for a generic version of cancer drug Nexavar. Mylan believes it is the first to file an ANDA, which should lead to 180 days of exclusive rights to sell its generic version before other generic manu- facturers can enter the market. Mylan will report December-quarter results on March 2, with the consensus projecting earnings per share of $1.05, up 35%, on revenue growth of 14%. Mylan is a Buy and a Long-Term Buy.
Richard Moroney, Dow Theory Forecasts, www.dowtheory.com, 219-852-3200, February 16, 2015